A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Clinical trial NCT03767751 · UNKNOWN
Trial details
- NCT number
- NCT03767751
- Sponsor
- Chinese PLA General Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-05
- Primary completion
- 2022-12-05
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.